Grab an umbrella, it's raining ⁠IPOs⁠!

FromBioSpace

Start listening View podcast show

Grab an umbrella, it's raining ⁠IPOs⁠!

FromBioSpace

ratings:

Length:

11 minutes

Released:

Jan 24, 2024

Format:

Podcast episode

Description

The first surge of IPO activity this year sees Alto Neuroscience, ArriVent Biopharma, CG Oncology, Kyverna Therapeutics and Metagenomi making announcements.
Lori, Greg and Tyler also discuss gene therapy pricing including Vertex/CRISPR's Casgevy.

Released:

Jan 24, 2024

Format:

Podcast episode

Titles in the series (46)

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Skip carousel

Q3 earnings recap: winners, losers & surprises by BioSpace
18 min listen
Zepbound vs Wegovy: a two horse race by BioSpace
14 min listen
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure by BioSpace
18 min listen
Integrating AI in life sciences to change employee behavior with Microsoft and IQVIA by BioSpace
21 min listen
Artificial Intelligence, Part 2: Human Interaction, Liability, and Patient Safety by BioSpace
17 min listen
Deals, Dupixent and GLP-1 drug shortages by BioSpace
17 min listen
The top life sciences startups to watch this year by BioSpace
15 min listen
Fast and furious evolution: how to ensure AI is catalyst for positive societal change with Microsoft and IQVIA by BioSpace
32 min listen
First ever CRISPR gene therapy approval: What happens next? by BioSpace
13 min listen
GLP-1 and ADC rollercoasters pick up speed by BioSpace
13 min listen
Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior by BioSpace
17 min listen
What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital by BioSpace
45 min listen
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny by BioSpace
17 min listen
On the ground at #JPM2024 - Day 3 highlights by BioSpace
12 min listen
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics by BioSpace
48 min listen
What VCs really think of the market right now with MPM Capital, Endeavor Venture Fund and Two Bear Capital by BioSpace
22 min listen
On the ground at #JPM2024 - Day 2 highlights by BioSpace
12 min listen
Grab an umbrella, it's raining ⁠IPOs⁠! by BioSpace
11 min listen
Optimistic, but for how long? Our big takeaways from #JPM2024 by BioSpace
14 min listen
Every move you make: biopharma industry under heavy scrutiny by BioSpace
16 min listen
On the ground at #JPM2024 - Day 1 highlights by BioSpace
10 min listen
Iovance wins with Amtagvi and the ADC train chugs on by BioSpace
14 min listen
What can biopharma expect from the job market? by BioSpace
18 min listen
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo by BioSpace
12 min listen
Keep calm and CAR-T on? by BioSpace
18 min listen
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars by BioSpace
14 min listen
Eyes on the prize: Novo buys Catalent by BioSpace
29 min listen
Historic approval for MASH, CAR-Ts in the spotlight by BioSpace
18 min listen
The skinny on weight loss, donanemab and the State of the Union by BioSpace
16 min listen
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now by BioSpace
11 min listen

More Episodes from BioSpace

Skip carousel

Bayer Layoffs, a Big Alzheimer’s Deal and ASGCT Wrap by BioSpace
15 min listen
Women's Health: Where Politics and Science Meet by BioSpace
22 min listen
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird by BioSpace
12 min listen
BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy by BioSpace
12 min listen
The IRA, BMS’ Big Cuts, First WHIM Approval by BioSpace
16 min listen
Where Do We Go From Here? The Future of Women's Health by BioSpace
22 min listen
Sanofi Layoffs, CAR-T Warnings and a New GLP-1 Player by BioSpace
18 min listen
Amylyx and ALS, Continued ADC Excitement, Dire Drug Shortages by BioSpace
20 min listen
It's a Design Problem: Women and Clinical Trials by BioSpace
20 min listen
Alphabet Soup: AACR and ACC Dominate Headlines This Week by BioSpace
17 min listen
Did WuXi Make a Whoopsie? US-China R&D Relations in Limbo by BioSpace
12 min listen
Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients? by BioSpace
22 min listen
Bayer’s sweeping executive cuts, Wegovy’s expanding reach by BioSpace
17 min listen
Money talk: Salary trends and raises by BioSpace
15 min listen
Historic approval for MASH, CAR-Ts in the spotlight by BioSpace
18 min listen
The unintended consequences of small molecules by BioSpace
25 min listen
The skinny on weight loss, donanemab and the State of the Union by BioSpace
16 min listen
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now by BioSpace
11 min listen
The gap is where the pain is: Drug pricing and patient costs by BioSpace
20 min listen
Sweet succession: Gonzalez, patent thickets and his triumph over biosimilars by BioSpace
14 min listen
Iovance wins with Amtagvi and the ADC train chugs on by BioSpace
14 min listen
Eyes on the prize: Novo buys Catalent by BioSpace
29 min listen
Balancing act: Patient access and innovation by BioSpace
21 min listen
Keep calm and CAR-T on? by BioSpace
18 min listen
What can biopharma expect from the job market? by BioSpace
18 min listen
Optimistic, but for how long? Our big takeaways from #JPM2024 by BioSpace
14 min listen
On the ground at #JPM2024 - Day 3 highlights by BioSpace
12 min listen
On the ground at #JPM2024 - Day 2 highlights by BioSpace
12 min listen
On the ground at #JPM2024 - Day 1 highlights by BioSpace
10 min listen
Alternative funding strategies to discuss at JPM with Halia Therapeutics, the ADDF and Triumvira Immunologics by BioSpace
48 min listen

Discover this podcast and so much more

Grab an umbrella, it's raining ⁠IPOs⁠!

Grab an umbrella, it's raining ⁠IPOs⁠!

Description

Titles in the series (46)

More Episodes from BioSpace